Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update

Gain Therapeutics, Inc. (NASDAQ:GANX) was the target of a significant drop in short interest in June. As of June 30th, there was short interest totalling 193,000 shares, a drop of 61.4% from the June 15th total of 500,300 shares. Based on an average daily trading volume, of 244,500 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.2% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on GANX. Chardan Capital restated a “buy” rating and issued a $6.00 price target on shares of Gain Therapeutics in a research report on Wednesday, March 27th. Oppenheimer reiterated an “outperform” rating and set a $9.00 price objective on shares of Gain Therapeutics in a research report on Tuesday, April 23rd. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research report on Thursday.

Gain Therapeutics Stock Up 1.5 %

Gain Therapeutics stock traded up $0.02 during midday trading on Friday, hitting $1.38. 270,476 shares of the company were exchanged, compared to its average volume of 210,893. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.77 and a quick ratio of 2.77. Gain Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $5.33. The company’s fifty day moving average price is $1.95 and its 200-day moving average price is $3.19. The company has a market cap of $24.91 million, a PE ratio of -0.92 and a beta of 0.35.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.08. On average, research analysts predict that Gain Therapeutics will post -1.03 EPS for the current fiscal year.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.